Alphamab Oncology Croissance future
Future contrôle des critères 5/6
Alphamab Oncology is forecast to grow earnings and revenue by 70.1% and 39.4% per annum respectively. EPS is expected to grow by 70.1% per annum. Return on equity is forecast to be -11.3% in 3 years.
Informations clés
70.1%
Taux de croissance des bénéfices
70.1%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 41.8% |
| Taux de croissance des recettes | 39.4% |
| Rendement futur des capitaux propres | -11.3% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 01 Oct 2024 |
Mises à jour récentes de la croissance future
Recent updates
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 720 | 201 | 243 | N/A | 3 |
| 12/31/2025 | 432 | -134 | -85 | N/A | 3 |
| 12/31/2024 | 338 | -103 | -55 | N/A | 3 |
| 6/30/2024 | 256 | -216 | -194 | -175 | N/A |
| 3/31/2024 | 237 | -213 | -217 | -189 | N/A |
| 12/31/2023 | 219 | -211 | -239 | -203 | N/A |
| 9/30/2023 | 234 | -214 | -277 | -215 | N/A |
| 6/30/2023 | 250 | -218 | -315 | -228 | N/A |
| 3/31/2023 | 208 | -272 | -372 | -264 | N/A |
| 12/31/2022 | 167 | -326 | -430 | -300 | N/A |
| 9/30/2022 | 183 | -309 | -423 | -275 | N/A |
| 6/30/2022 | 200 | -292 | -416 | -251 | N/A |
| 3/31/2022 | 173 | -352 | -447 | -286 | N/A |
| 12/31/2021 | 146 | -412 | -479 | -321 | N/A |
| 9/30/2021 | 73 | -502 | -499 | -368 | N/A |
| 6/30/2021 | N/A | -592 | -519 | -415 | N/A |
| 3/31/2021 | N/A | -510 | -478 | -381 | N/A |
| 12/31/2020 | N/A | -428 | -438 | -347 | N/A |
| 9/30/2020 | 1 | -652 | -422 | -305 | N/A |
| 6/30/2020 | 2 | -877 | -406 | -263 | N/A |
| 3/31/2020 | -1 | -851 | -423 | -261 | N/A |
| 12/31/2019 | 5 | -833 | -397 | -225 | N/A |
| 9/30/2019 | 3 | -495 | -347 | -201 | N/A |
| 6/30/2019 | 1 | -157 | -298 | -177 | N/A |
| 3/31/2019 | 6 | -176 | -207 | -113 | N/A |
| 12/31/2018 | -1 | -150 | -167 | -94 | N/A |
| 12/31/2017 | 1 | -33 | N/A | -65 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 9966 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Bénéfices vs marché: 9966 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: 9966 is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: 9966's revenue (39.4% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
Croissance élevée des revenus: 9966's revenue (39.4% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 9966 is forecast to be unprofitable in 3 years.